OncoImmune develops novel immune-modulators targeting innate checkpoint mechanisms involving CD24–Siglec10 signaling as well as potential best-in-class anti-CTLA-4 antibody therapy that can ...

ONC-841 is a potential first-in-class SIGLEC 10 antibody designed to block an innate and potentially adaptive immune ...

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical ...

Tissue engineering is a set of methods that can replace or repair damaged or diseased tissues with natural, synthetic, or semisynthetic tissue mimics. These mimics can either be fully functional ...